An acquired V617F JAK2 mutation occurs in patients with polycythemia vera (PV) or essential thrombocythemia (ET). In a proportion of V617F-positive patients, mitotic recombination produces mutation-homozygous cells that come to predominate with time. However, the prevalence of homozygosity is unclear, as previous reports studied mixed populations of wildtype, V617F-heterozygous and V617F-homozygous mutant cells. We therefore analysed 1766 individual hematopoietic colonies from 34 patients with PV or ET in whom granulocyte sequencing demonstrated that the mutant peak did not predominate. V617F-positive BFU-e were more frequent in PV patients compared to ET patients (p=0.022) and, strikingly, V617F-homozygous BFU-e were detected in all 17 PV patients, but in none of the ET patients (p<0.0001). Moreover, mutationhomozygous cells were present in two ET patients after polycythemic transformation.
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ABSTRACT
An acquired V617F JAK2 mutation occurs in patients with polycythemia vera (PV) or essential thrombocythemia (ET). In a proportion of V617F-positive patients, mitotic recombination produces mutation-homozygous cells that come to predominate with time. However, the prevalence of homozygosity is unclear, as previous reports studied mixed populations of wildtype, V617F-heterozygous and V617F-homozygous mutant cells. We therefore analysed 1766 individual hematopoietic colonies from 34 patients with PV or ET in whom granulocyte sequencing demonstrated that the mutant peak did not predominate. V617F-positive BFU-e were more frequent in PV patients compared to ET patients (p=0.022) and, strikingly, V617F-homozygous BFU-e were detected in all 17 PV patients, but in none of the ET patients (p<0.0001). Moreover, mutationhomozygous cells were present in two ET patients after polycythemic transformation.
These results demonstrate that V617F-homozygous erythroid progenitors are present in the vast majority of patients with PV but occur rarely in those with ET.
INTRODUCTION
An acquired V617F mutation in the tyrosine kinase JAK2 occurs in most patients with polycythemia vera (PV) and in half of those with essential thrombocythemia (ET) or idiopathic myelofibrosis [1] [2] [3] [4] [5] . This mutation increases JAK2 kinase activity [2] [3] [4] [5] , confers cytokine independence on cell-lines [2] [3] [4] [5] , is required for erythropoietin (Epo)-independent erythroid progenitor growth in affected patients 1, 3 , and produces erythrocytosis in a retroviral bone marrow transplant model 3 . JAK2 mutation status divides ET patients into two distinct subgroups, with V617F-positive patients resembling a forme fruste of PV 6 .
These data have led to the suggestion that V617F-positive ET and PV form a disease continuum, with the extent of erythrocytosis influenced by a combination of genetic and physiological modifiers 6 .
Homozygosity for the V617F mutation occurs in 30% of patients with PV preparation and JAK2 sequence analysis were performed as described 1 . Sequence patterns were scored as V617F-heterozygous if the mutant peak was <50% total peak height. Peripheral blood burst forming unit-erythroid (BFU-e), Epo-independent erythroid colonies (EECs) and colony forming unit-granulocyte/macrophage (CFU-GM)
were genotyped by BsaXI digestion 1, 13 . BsaXI digestion of JAK2 exon 14 was confirmed by digestion of a control (SCL) fragment and/or by sequencing of colony DNA in all 700 colonies so analyzed.
Statistical Methods. Frequencies of V617F-positive and V617F-homozygous colonies
in ET and PV patients were compared using an unpaired Student's t-test. Frequencies of V617F-homozygous colonies were compared in V617F-positive ET patients that had not transformed and those that had transformed to PV using the Fisher's exact test. To assess the relationship between clinical/laboratory characteristics and the proportion of either V617F-homozygous BFU-e or V617F-positive BFU-e, logistic regression models
were fitted, and significance tested using likelihood ratio tests.
RESULTS & DISCUSSION
We identified five patients with PV and a V617F-homozygous sequence pattern in their granulocytes (mutant peak >50% total peak height) for whom an earlier granulocyte DNA sample was available. In 3 cases, the earlier samples (taken 2, 5 or 6 years previously) had a heterozygous pattern ( Figure 1A ). These results demonstrate that V617F-homozygous clones may predominate with time, and are consistent with the concept that patients with an apparently V617F-heterozygous sequence pattern may harbor a subpopulation of V617F-homozygous cells.
We therefore analysed 1082 hematopoietic colonies from seventeen PV patients with a heterozygous sequence pattern recorded in their peripheral blood granulocytes in the preceding six months. These were assessed by BsaXI digestion 1, 6, 13 , which distinguishes between wildtype, V617F-heterozygous and V617F-homozygous genotypes ( Figure   1B ). As expected, BFU-e from a patient with a homozygous granulocyte sequence pattern were predominantly V617F-homozygous ( Figure 1C , patient 19). However, V617F-homozygous BFU-e were also present in all patients with a heterozygous granulocyte sequence (patients 1-17). To exclude the possibility that the BsaXI site was destroyed by mutations other than the 1849G>T (V617F) mutation, exon 14 was sequenced in colonies with a restriction pattern consistent with a V617F-homozygous genotype. In 48 colonies from 8 PV patients, the 1849G>T mutation was detected in both JAK2 alleles. The frequencies of V617F-homozygous or total V617F-positive BFU-e did not correlate significantly with age, gender, disease duration or treatment, or with hemoglobin levels, white cell counts or platelet counts either at diagnosis or the time of analysis (p>0.5 for all variables). All patients analysed within three months of diagnosis had V617F-homozygous BFU-e ( Figure 1C ; patients 2-4, 9, 11), suggesting Figure 1A ). Ninety-six CFU-GM colonies from six PV patients were also analysed (Supplemental Figure 1B) .
Mutation-homozygous colonies were identified in five cases, demonstrating that the mutational event responsible for V617F homozygosity occurs at or before the common myeloid progenitor stage. In each patient, the proportions of CFU-GM and BFU-e that were V617F-positive were comparable, as were the proportions of CFU-GM and BFU-e that were V617F-homozygous, suggesting that this mutation does not strongly bias commitment towards the erythroid lineage. and 34) were V617F-homozygous, compared to 130/270 EECs from the PV patients (p<0.0001). These data demonstrate that, in contrast to PV patients, ET patients rarely harbor V617F-homozygous erythroid progenitors, although the existence of rare ET patients with mutation-homozygous progenitors cannot be excluded. There are at least three possible explanations for these striking results. Firstly, these PV patients are likely to have lower serum erythropoietin levels than the ET patients, and V617F-homozygous BFU-e may have a selective advantage in a low erythropoietin environment. However, for individual PV patients, the fractions of V617F-homozygous BFU-e and CFU-GM were similar, suggesting that selection for homozygosity occurred
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in multipotent progenitors and was therefore unlikely to be dependent on the erythropoietin receptor, which is first expressed at the BFU-e stage of differentiation 14 .
Secondly, compared to ET patients, PV patients may have a longer pre-diagnosis phase of their disease, allowing more time for homozygosity to occur. Thirdly, mitotic recombination involving the JAK2 locus may occur more frequently in patients with PV.
It is recognised that patients with ET may infrequently transform to PV 15, 16 . We therefore studied two patients who presented with V617F-positive ET and no evidence of erythrocytosis, but who developed PV 36 or 147 months after their initial diagnosis.
V617F-homozygous BFU-e and EECs were present in both patients after polycythemic transformation (p=0.0058; Figure 2B ). Colony data from the time of their presentation with ET are not available, so we cannot exclude the possibility that these patients had V617F-homozygous colonies prior to transformation. However, taken together with the absence of detectable V617F-homozygous BFU-e in all ET patients, our results raise the possibility that, in some patients, duplication of the mutant JAK2 allele with loss of the normal allele may be associated with a phenotypic change from thrombocythemia to polycythemia. 
